New analyses on efficacy of Ofev across various patient populations with IPF

German family-owned pharma major Boehringer Ingelheim has released three new post-hoc analyses from the Phase III INPULSIS trial, the first analysis showing treatment with Ofev (nintedanib) has similar and consistent effects on disease progression (as measured by annual rate of forced vital capacity [FVC] decline) and the amount of time to the first acute exacerbation - regardless of whether people with idiopathic pulmonary fibrosis (IPF) enrolled in the trials in the USA or internationally.

Ofev was approved for the treatment of IPF in the USA in October 2014 and in Europe at the start of this year (The Pharma Letter January 19).

"In a rare lung disease like IPF, which has unique characteristics and affects people around the world, it is critical to help pulmonologists make informed treatment decisions by understanding the effectiveness of Ofev in these different patient populations," said John Huggins, Associate Professor Department of Medicine, Medical University of South Carolina, adding: "This new analysis showed that Ofev is comparably effective in people with IPF regardless of where they were enrolled in the trial."